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Aims Chronic heart failure (CHF) due to left ventricular systolic dysfunction is associated with poor quality of life (QoL).
This study aimed to assess factors affecting health-related QoL in CHF patients and their carers and the impact of
QoL on clinical outcomes.
Methods
and results
Demographic, social, and clinical data were collected for consecutive CHF patients in an academic hospital setting. All
patients (n ¼ 179) and informal carers (n ¼ 131) completed a generic QoL questionnaire (EQ-5D) and patients also
completed a CHF-specific QoL questionnaire (Minnesota Living with Heart Failure Questionnaire, MLHFQ). Patients
were then followed up for 3 years to assess subsequent hospitalizations and mortality. Minnesota Living with Heart
Failure Questionnaire score was independently predicted by NYHA class, socioeconomic deprivation and lack of an
informal carer. Severity of heart failure, anaemia, and cancer co-morbidity in CHF patients were associated with poor
QoL in carers. Chronic heart failure patients with poor baseline QoL (MLHFQ. median) were at increased risk of
hospital admissions [hazard ratios (HR) 7.3, P, 0.001] and death (HR 1.5, P ¼ 0.09). Mortality was also indepen-
dently associated with repeat hospitalization (HR 6.0, P, 0.001) and lack of beta-blocker therapy (HR 1.8, P ¼ 0.03).
Conclusion Severe heart failure, poor socioeconomic status and lack of social support results in poor QoL in CHF patients which
in turn leads to an increased risk of hospital admissions and death. Quality of life in carers is lower in female carers,
those with socioeconomic deprivation and those caring for patients with higher NYHA class or having a cancer.
Quality of life assessment may complement clinical prognostic markers to identify CHF patients at high risk of
adverse events.
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Introduction
Chronic heart failure (CHF) due to left ventricular systolic dysfunc-
tion (LVSD) is associated with significant morbidity and in
advanced stages has a mortality worse than many cancers.1 A
recent report has demonstrated that widespread use of evidence-
based drugs and devices over the last 10 years has resulted in sig-
nificant improvements in survival in CHF patients.2 Although
improving survival remains clinically important, many patients
with advanced heart failure give equal or more importance to
quality of life (QoL) when compared with length of life.3 Quality
of life in patients with heart failure is not only significantly
reduced when compared with the general population, but CHF
also causes more severe impairment of physical and psychosocial
functioning than other chronic diseases such as chronic airway
disease, arthritis and ischaemic heart disease.4 Quality of life,
symptom burden and emotional well-being in CHF patients is
indeed as poor as in patients with cancer.5 Improving QoL is
increasingly being recognized as a major aim of treatment in clinical
practice and as an outcome measure in clinical trials.6 Previous
studies exploring factors affecting QoL have focused mainly on
clinical variables, overlooking the impact of psychosocial variables,
potential interaction of clinical and non-clinical variables and inter-
action of QoL in patients and carers.7 The effect of QoL on
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subsequent CHF-related adverse events has previously been
reported in the literature.6,8–11 However, these studies often
included selected subgroups of CHF patients, were performed
on sub-sets within clinical trials or had relatively short follow-up.
This study aimed to explore the effects of a wide range of clinical,
social, psychological, and demographic factors on QoL in an unse-
lected cohort of CHF patients and their informal carers and to
investigate the impact of baseline QoL on hospitalization and mor-
tality over a 3-year follow-up period.
Methods
The study was approved by Lothian Research Ethics Committee and
conforms to the principles outlined in the Declaration of Helsinki.
All subjects gave written informed consent to participate.
Study participants
Consecutive patients with CHF (n ¼ 179), diagnosed clinically using
Framingham criteria and confirmed to have LVSD on echocardiogra-
phy, were identified either from cardiology wards at time of discharge
(n ¼ 101) or outpatient clinics (n ¼ 78). Demographic, social, and clini-
cal data were collected for all the patients from computerized hospital
and primary care records. Where the patient identified a specific infor-
mal carer, a family member or a close friend, these individuals (n ¼
131) were also asked to complete a QoL questionnaire and their
basic demographic details (age, gender, and postcode) were documen-
ted. Socioeconomic status was derived from the patients and carers
postcode (zipcode) using the Scottish Index of Multiple Deprivation
(SIMD) which provides a numeric score, ranging from 0.54 (least
deprived) to 87.6 (most deprived), based on a national census examin-
ing employment status, education and skills, housing, average income,
and access to services.12
Quality of life assessment
Quality of life was assessed using European QoL-5 Dimensions
(EQ-5D) and Minnesota Living with Heart Failure Questionnaire
(MLHFQ). European QoL-5 Dimensions is a standardized instrument
to provide a single-index value for health-related QoL and has been
validated in general population and heart failure patients.13 Minnesota
Living with Heart Failure Questionnaire has been widely used and vali-
dated to assess QoL in CHF patients and to explore effect of different
interventions. All patients completed both EQ-5D and MLHFQ, at
least 1 month after discharge or at the time of attendance at an out-
patient clinic. The informal carers completed EQ-5D questionnaire
at baseline. Questionnaires were sent to patients and carers by post
and were followed up by a single phone call if no response was
received within 2 weeks.
Follow-up
Mean follow-up period in this study was 40 months (range 33–45).
Total number of hospital admissions and CHF-related hospital admis-
sions during follow-up were assessed using hospital records and local
computerized patient administration system. All-cause mortality was
assessed using the national Central Health Index database.
Statistical analyses
Data are presented as Mean+ SEM or as percentages (proportions)
unless stated otherwise. Analysis was carried by using student’s t-test
or one-way ANOVA for parametric data, Mann–Whitney U-test for
non-parametric data and x2 or Fisher’s exact test for categorical
data. Variables with significant trend (P, 0.1) were entered in multiple
regression analysis models to determine the influence of variables on
QoL and CHF-related hospital admissions. For mortality analysis, Cox
proportional-hazards regression survival model was used. The hazard
ratios (HR) with confidence interval (CI) and P values are presented.
For parameters demonstrating significance in the multivariate analysis,
survival curves were computed using the Kaplan–Meier method. All
statistical analyses were performed using SPSS for windows version
17.0 (SPSS Inc., Chicago, USA).
Results
Patient characteristics
The overall study cohort included 179 patients and 131 informal
carers. The mean age was 71 years for CHF patients and 63
years for carers. Seventy-two per cent of the patients and 16%
of carers were males. Nearly two-thirds (62%, n ¼ 110) of CHF
patients had ischaemic heart failure. The remainder (38% patients
with non-ischaemic aetiology) had hypertension (13%), valvular
heart disease (9%), alcoholic cardiomyopathy (5%), and idiopathic
dilated cardiomyopathy (10%). The baseline clinical, social, and
demographic characteristics for all participants are described in
Table 1.
Quality of life in chronic heart failure
patients
Chronic heart failure patients had poor QoL with a mean QoL
score of 50+2 on MLHFQ and 0.57+ 0.03 on EQ-5D question-
naire. There was a strong correlation between the EQ-5D and
MLHFQ scores (Spearman correlation coefficient 20.75, CI
20.67 to 20.81, P ≤ 0.001).
Chronic heart failure patients with poor QoL were younger,
predominantly male, with lower socioeconomic status, higher
NYHA class, more likely to have chronic airway disease and less
likely to be taking beta-blocker drug therapy (Table 1).
Variables with a test of significance at P, 0.1 by univariate
analysis were entered into a multiple regression model. After
adjustment for all variables, lower QoL (higher MLHFQ score) in
CHF patients was independently associated with more severe
heart failure symptoms (NYHA class), lower socioeconomic
status (SIMD score) and not having an informal carer (Table 2).
Quality of life in carers
Quality of life of carers was better than CHF patients (EQ-5D
0.76+ 0.02 vs. 0.57+0.03, P ¼ 0.02). Quality of life of carers
also correlated with QoL of patients; people caring for CHF
patients with poor QoL had lower QoL scores than carers of
patients with good QoL (0.72+ 0.01 vs. 0.83+ 0.01, P ¼ 0.01).
Quality of life was particularly low in female carers compared
with male carers (0.74+0.02 vs. 0.86+ 0.05, P ¼ 0.03). More-
over, carer QoL was also affected by patient-related factors includ-
ing severity of heart failure symptoms, presence of anaemia or a
cancer. Multiple regression analysis demonstrated that carers
QoL was independently associated with carer’s sex, carer depri-
vation (SIMD score), patient NYHA class, and patient co-morbidity
with a cancer (Table 2).
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Table 1 Baseline characteristics of patients and carers
Variables Entire group QoL groups
MLHFQ < Median (Good QoL) MLHFQ > Median (Poor QoL) P*
Patients Demographic and Social
Age (years) 71+1 73+1 69+2 0.02
Male (%) 72 64 81 0.01
SIMD score 17.0+1.1 12.2+1.2 21.9+1.6 ,0.001
Home owner (%) 47 50 44 ns
Institutional care (%) 2.3 2.2 2.4 ns
Pts. having a carer (%) 72 82 69 0.09
Pts. living with carer (%) 48 51 45 ns
Clinical profile
LVSD
Mild (%) 30 33 25 ns
Moderate (%) 42 40 45 ns
Severe (%) 28 28 30 ns
NYHA
I and II (%) 59 78 39 ,0.001
III and IV (%) 41 22 61 ,0.001
CHF aetiology
Ischaemic (%) 62 62 61 ns
Non-ischaemic (%) 38 38 39 ns
Creatinine (mmol/L) 121+3 116+4 124+4 ns
Haemoglobin (g/dL) 131+2 131+1 130+2 ns
Duration of CHF (m) 27.7+3 29.7+4 25.5+4 ns
Co-morbidities (%)
Chronic obstructive pulmonary disease 8.5 4.4 12.6 0.05
Diabetes 29 24 34 0.09
Hypertension 44 44 44 ns
Arthritis 9.6 6.6 12.6 ns
Cancer 8 10 6 ns
Stroke 6.8 6.7 6.9 ns
Depression 5.1 4.4 5.7 ns
Medication (%)
Beta-blockers 56 66 45 0.003
Diuretics 93 94 92 ns
ACE Inhibitors 71 72 70 ns
Spironolactone 33 12 21 0.03
Statins 55 51 59 ns
Digoxin 46 42 51 ns
Carer characteristics
Age (years) 63+1 63+1 63+2 ns
Male (%) 16 21 6 0.02
SIMD score 16.3+1.8 13.8+1.7 18.8+2.O 0.05
EQ-5D score 0.76+0.03 0.83+0.0 0.72+0.0 0.01
Daily visit to patient (%) 57 53 62 ns
Full time job (%) 31 43 13 0.001
SIMD, Scottish Index of Multiple Deprivation; LVSD, Left Ventricular Systolic Dysfunction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; ns, non-significant.
*P-value was calculated using student’s t-test/Man–Whitney U-test for continuous data and x2 test/Fisher’s exact test for categorical data.
J. Iqbal et al.1004
 at Edinburgh U
niversity on June 19, 2013
http://eurjhf.oxfordjournals.org/
D
ow
nloaded from
 
Effect of quality of life and other variables
on mortality
During the follow-up period of 3 years (average 40 months), 67
patients (37%) died. There were significantly more deaths in
patients with poor QoL (MLHFQ. median) when compared
with patients with higher QoL score at baseline (46 vs. 31%, P ¼
0.03). Patients in the lowest baseline MLHFQ QoL quartile (Q4)
had a worse prognosis than other groups (HR 1.7, CI 1.1–2.9,
P ¼ 0.03, Figure 1A). Other factors associated with survival using
univariate analysis were age, CHF-related hospital admissions,
NYHA class, lack of beta-blocker and lack of ACE inhibitor
therapy, haemoglobin and creatinine levels, and co-morbidity
with cancer (Table 3).
Using Cox proportional hazards model, CHF-related hospital
admissions (HR 6.0, CI 3.3–10.0, P, 0.001) and lack of beta-
blocker therapy (HR 1.8, CI 1.1–2.8, P ¼ 0.03) emerged as inde-
pendent factors affecting survival whereas presence of cancer
co-morbidity (HR 1.5, CI 0.9–2.8, P ¼ 0.07) and poor QoL (HR
1.5, CI 0.9–2.9, P ¼ 0.1) demonstrated a trend (Figure 2).
Effect of quality of life and other variables
on hospital admissions
Hospital admissions were significantly greater in patients with poor
base-line QoL when compared with better QoL group (No. of
CHF admissions: 4.8+0.8 vs. 1.5+0.3, P ¼ 0.004). Detailed
analysis by comparison of QoL quartiles showed a significant step-
wise increase in number of CHF-related hospital admissions with
worsening QoL at baseline (Figure 1B). Other factors associated
with hospital admission by univariate analysis, included NYHA
class (P, 0.001), age (P, 0.001), MLHFQ score (P, 0.001), dur-
ation of CHF (P, 0.001), use of ACE inhibitors (P, 0.01) and
beta-blockers (P, 0.01), creatinine level (P, 0.01), depression
(P, 0.05), gender (P ¼ 0.05), haemoglobin level (P ¼ 0.05), and
co-morbidity with diabetes (P ¼ 0.05). These factors were
included in multiple regression analyses to identify independent
variables affecting total (all-cause) and CHF-related hospital admis-
sions and results are summarized in Table 4.
Discussion
This study provides a contemporary and comprehensive evaluation
of the influence of clinical, social, and socioeconomic variables on
QoL in CHF patients and their informal carers. The findings high-
light the association between QoL, recurrent hospitalization and
mortality in CHF patients.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 2 Factors independently associated with quality
of life in chronic heart failure patients and carers
QoL (MLHFQ score) in CHF
patients
QoL (EQ-5D score) in
carers
Variable P* Variable P*
NYHA class ,0.001 NYHA class of patient 0.02
SIMD score 0.002 Caring patient with a
cancer
0.01
Patient without informal
carer
0.01 Carer’s gender 0.03
Carer’s SIMD score 0.04
SIMD, Scottish Index of Multiple Deprivation; MLHFQ, Minnesota Living with
Heart Failure Questionnaire.
*P-value from multiple regression analysis.
Figure 1 Baseline quality of life predicts mortality and hospital admissions. Chronic heart failure patients in worst quality of life (MLHFQ
score) quartile (Q4) had significantly higher mortality (P ¼ 0.03) in 3-year follow-up period (A). MLHF quartiles also correlate significantly
with chronic heart failure-related hospital admissions (B). One-way ANOVA showed a significant difference between the four groups
(P, 0.01). Post hoc analysis with Tukey’s multiple comparison test showed significant difference between Q1 and Q4 (P, 0.01) and also
between Q2 and Q4 (P, 0.05).
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Factors affecting quality of life in chronic
heart failure patients and carers
NYHA class, socioeconomic deprivation (SIMD score) and pres-
ence of an informal carer emerged as three independent predic-
tors of QoL in CHF patients, after adjustment for confounding
variables. NYHA class has been shown to correlate well with
QoL in a number of studies.7,14 However, there are few studies
that have examined socioeconomic deprivation using a validated
tool and only one that found an association with current or
former occupational status.15 Our study, using a tool for multiple
measures of deprivation, provides stronger evidence for this
association. Our study also indicated that patients who did not
have an informal carer had a worse QoL than those who could
identify a carer. It has been shown previously that QoL in CHF
patients having a marital relationship is better than the CHF
patients living alone16 and also the changes in social support can
influence health-related QoL.17 Our findings, therefore, further
highlight the importance of home-support for CHF patients. The
effect of age on QoL in heart failure patients is not as clear as in
the general population where increasing age leads to progressive
reduction in QoL. Some studies have reported worsening QoL
with age15 and other studies have reported opposing results.14
Our data suggest that younger CHF patients have worse QoL
than older patients but this association was not strong and
became non-significant after adjustment for other variables.
Figure 2 Kaplan–Meier survival curves. Survival in chronic heart failure patients was associated with number of chronic heart failure-related
hospital admissions (A), usage of beta-blockers (B), co-morbidity with any cancer in chronic heart failure patients (C ) and baseline quality
of life (D).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Variables affecting survival in chronic heart
failure patients (Kaplan–Meier univariate analysis)
Variables Groups Survival
(months)
P
CHF
hospitalization
0–1 CHF admission per year 44.3 ,0.001
.1 CHF admission per year 26.7
Beta-blockers Patients receiving drug 39.7 0.001
Patients NOT receiving drug 31.8
NYHA class Class I and II 39.5 0.002
Class III and IV 31.3
Cancer Patient without cancer 36.9 0.003
Patient with cancer 28.1
Creatinine
(mmol/L)
Less than 130 (median) 38.4 0.03
More than 130 (median) 33.3
MLHFQ Score Score less than 50 (median) 38.5 0.04
Score more than 50
(median)
33.9
ACE Inhibitors Patients receiving drug 38.0 0.04
Patients NOT receiving drug 30.9
Haemoglobin
(g/dL)
More than 120 (median) 38.4 0.08
Less than 120 (median) 33.8
Age (years) Less than 70 (median) 37.5 0.09
More than 70 (median) 33.3
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Quality of life in carers, assessed by EQ-5D, was slightly lower
than expected in the general population.18 Female carers demon-
strated overall poorer QoL than male carers which is consistent
with previous observations in partners of CHF patients.19 The
underlying cause of this gender difference remains uncertain and
merits further study. An association between QoL in patients
and cares has been observed in studies of cancer patients.20 In
our study, although the QoL scores in patients were closely associ-
ated with QoL scores in their informal carers, after statistical
adjustment for confounding factors this association was no
longer significant. One might expect some link between carers
QoL and patients hospital admissions, however, we did not find
an association between carers QoL and CHF-related events in
patients. On the other hand, severity of heart failure, presence
of anaemia, and co-morbidity with a cancer in CHF patients
were found to be independently linked to QoL of carers.
Factors affecting hospitalization and
mortality
Heart failure is a leading cause of hospital admission, particularly in
elderly patients, placing a significant burden on health care
resources. This longitudinal study suggests that CHF hospitalization
is a strong independent predictor of mortality. This important
finding reinforces the findings of other studies21–23 and highlights
the need for greater emphasis on interventions that reduce hospi-
talizations. Our findings also potentially support the use of using
heart failure hospital admissions as a marker in identifying patients
who may be reaching end of life.24
Cancer co-morbidity was independently associated with mor-
tality in our study population. There were only 14 patients with
the combined diagnosis of CHF and a malignancy but it is clear
that this group merits special attention in the clinical setting with
early consideration for extra supportive care regardless of the per-
ceived clinical prognosis.
The finding that lack of use of beta-blocker drugs was linked to
both mortality and hospitalization underscores the significant
benefits that are lost in CHF patients with LVSD not treated with
beta-blockers and is consistent with previous literature.25 Chronic
heart failure patients in our study were managed within a specialized
cardiology service either by a multidisciplinary team led by specialist
nurses or in a consultant-led cardiology outpatient setting. Therefore,
although the overall use of beta-blockers appears low, it is likely that
this was due to co-morbidities or intolerance. In support of this,
patients not on beta-blockers were older, had significantly more
chronic obstructive pulmonary disease, anaemia, low blood pressure,
and renal impairment (data not shown). It is likely that a combination
of the absence of beta-blockers (and their attendant benefits) and the
presence of these co-morbidities confer poorer outcome.
Clinical implications
The Advanced Heart Failure Study Group of the European Society
of Cardiology has recently stressed the need for promoting the
development of heart failure oriented palliative care services
across Europe.26 However, it is well acknowledged that identifi-
cation of CHF patients approaching end of life and in need of pal-
liative care can be extremely difficult.5,26 One approach is to use
clinical prognostic models based on patient cohorts from
acute27–29 and ambulant23,30,31 CHF populations. Whereas
helpful, these models have major limitations in that they primarily
focus on clinical factors, they are based on assessment of prognosis
in populations and not individual patients,32 and some are based on
datasets derived from randomized controlled trials.23,28 The UK
national Gold Standards Framework (GSF) includes NYHA class
(III and IV) and repeated hospitalization as tools to identify patients
at end of life due to CHF24 and these factors were also identified as
important in our study. Our study suggests that QoL assessed by
MLHFQ may complement clinical markers of poor prognosis.
Formal measurement of QoL as a routine part of clinical assess-
ment may not only identify patients with a poor composite QoL
score but may also allow the care provider to address-specific
QoL domains in a way that is of benefit to the individual patient.
Serial assessment of QoL may also provide additional valuable
information regarding disease progression, response to interven-
tions and prognosis and merits further study.
Study limitations
This study has several potential limitations. The number of patients
and carers enrolled in this study is relatively small; however, we
analysed a large number of variables covering clinical and social
characteristics not included in previous studies. Furthermore, our
study included unselected patients from routine clinical settings
with follow-up for 3 years. This makes our finding more relevant
to real life clinical practice. Further possible limitations of our
study include lack of data on biochemical markers of CHF including
brain natriuretic peptide (BNP) which has been shown to have
association with CHF outcome.14 However, BNP was not available
in our centre at the time of this study. We only included patients
with LV systolic dysfunction, so results may not be applicable to
heart failure patients with preserved systolic function and
additional studies may be needed to address this issue.
Conclusion
In conclusion, this study indicates that higher NYHA class, poor
socioeconomic status and lack of informal carer results in poor
QoL in CHF patients. Quality of life in carers is lower in female
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Factors independently associated with
hospitalization in chronic heart failure patients
Variable CHF
admissions*
Total
admissions*
QoL score ,0.0001 0.02
Beta-blockers usage 0.04 ns
NYHA ns 0.01
ACE Inhibitors usage ns 0.01
Chronic obstructive
pulmonary disease
ns 0.03
Age ns 0.04
ns, non-significant P-value.
*P values from multiple regression analyses.
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carers, those with socioeconomic deprivation and those caring for
patients with higher NYHA class or having a cancer. Poor QoL in
patients predicts an increased risk of CHF-related and all-cause
hospital admissions. Repeated hospitalization, lack of use of beta-
blockers, co-morbidity with a cancer, and poor QoL are associated
with higher mortality in CHF patients. Patient assessment proto-
cols for CHF should combine clinical prognostic factors and self
reported QoL scoring to identify those at risk of recurrent hospi-
talization and death.
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